In a recent genetic study of CHD1,2, de novo mutations were estimated to contribute to 10–30% of syndromic cases who had additional congenital anomalies or neurodevelopmental disorders (NDD), but only about 4% of isolated cases who did not have additional anomalies or NDD. This evidence concerns the gene CHD1 and neurodevelopmental disorder.